drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
HER3 (ERBB3)-targeting antibody–drug conjugate that delivers a topoisomerase I inhibitor payload; administered IV every 3 weeks; binds HER3, internalizes, and releases a DNA-damaging topo-I payload to kill HER3-expressing tumor cells; tested alone and with trastuzumab or osimertinib.
nci_thesaurus_concept_id
C200456
nci_thesaurus_preferred_term
Anti-HER3/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1310
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3; ErbB3) conjugated, via a maleimide tetrapeptide-based cleavable linker, to a cytotoxic DNA topoisomerase I inhibitor, with potential antineoplastic activity. Upon administration of anti-HER3 ADC DB-1310, the anti-HER3 antibody moiety targets and binds to HER3 expressed on tumor cells. Upon internalization, the topoisomerase I inhibitor targets and binds to DNA topoisomerase I, thereby stabilizing the cleavable complex between topoisomerase I and DNA and resulting in DNA breaks, inhibition of DNA replication and apoptosis in HER3-expressing tumor cells. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in tumors.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER3 IgG1 antibody-drug conjugate linked via a cleavable linker to a topoisomerase I inhibitor. After binding HER3 on tumor cells, the ADC is internalized and releases the topo I inhibitor, stabilizing the topo I–DNA complex to induce DNA breaks, block DNA replication, and trigger apoptosis in HER3-expressing tumor cells.
drug_name
DB-1310
nct_id_drug_ref
NCT05785741